文献速递消化系统肿瘤

晚期胰腺癌中可溶性uPAR裂解形式升高与不良生存相关

Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer.
PubMed 文献 · Eur J Cancer · 2025-11-04

研究纳入344例晚期胰腺腺癌(PDAC)患者,于诊断及治疗前采集血浆,检测uPAR(I)和总suPAR(I-III+II-III)水平,分训练队列229例和验证队列115例。多因素Cox分析显示,uPAR(I)升高是总生存的独立预测因子(HR=1.39,95%CI 1.17-1.66,p<0.05,c-index=0.70),suPAR(I-III+II-III)结果类似(HR=1.48,95%CI 1.17-1.88,p<0.0001,c-index=0.69),并在验证队列中确认。结论认为这些标志物独立于CA19-9水平,具有潜在预后价值。

要点

  • 治疗前血浆uPAR(I)升高与晚期PDAC总生存差独立相关,HR=1.39。
  • suPAR(I-III+II-III)升高同样提示不良生存,HR=1.48。
  • 上述关联独立于CA19-9,并在验证队列中确认。

核心结论

  • 晚期PDAC患者治疗前血浆uPAR(I)和suPAR(I-III+II-III)升高与较差总生存相关,且独立于CA19-9水平。
  • 这些可溶性uPAR形式在该人群中具有潜在预后价值。

研究设计与样本

  • 研究纳入2008-2014年丹麦BIOPAC研究中的344例晚期胰腺腺癌患者,于诊断时和治疗前采集血浆。
  • 患者分为训练队列229例和验证队列115例,采用时间分辨荧光免疫分析法测定uPAR(I)和总suPAR(I-III+II-III)水平。
  • 采用Cox比例风险模型进行单因素和多因素分析,调整suPAR形式、年龄、体能状态、性别、CA19-9和Charlson合并症评分。

主要发现

  • 训练队列中,治疗前uPAR(I)升高是总生存的独立预测因子(HR=1.39,95%CI 1.17-1.66,p<0.05,c-index=0.70)。
  • suPAR(I-III+II-III)结果类似(HR=1.48,95%CI 1.17-1.88,p<0.0001,c-index=0.69)。
  • 验证队列确认uPAR(I)(p<0.0001,c-index=0.65)和suPAR(I-III+II-III)(p<0.0001,c-index=0.65)的预后关联。

临床怎么用

  • 治疗前检测血浆uPAR(I)或suPAR(I-III+II-III)可能辅助晚期PDAC预后分层,独立于CA19-9。
  • 该标志物目前仅为潜在预后指标,尚不能用于治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Different forms of urokinase plasminogen activator receptor (uPAR) in tissues and plasma are associated with poor prognosis in several types of cancers. This study aimed to determine whether different forms of soluble uPAR (suPAR) in pretreatment plasma samples from patients with advanced pancreatic adenocarcinoma (PDAC) have prognostic potential. PATIENTS AND METHODS: Plasma samples were collected at diagnosis and before treatment from 344 patients with advanced PDAC who were enrolled in the Danish BIOPAC study from to 2008-2014. The patients were divided into a training cohort (n = 229) and a validation cohort (n = 115). Plasma levels of suPAR were determined using time-resolved fluorescence immunoassays measuring uPAR domain I (uPAR(I)) and total suPAR (intact and cleaved forms: suPAR(I-III+II-III)). Cox proportional hazards models adjusted for suPAR forms, age, performance status, sex, CA19-9, and Charlson comorbidity score were used for univariate and multivariate analyses. RESULTS: Elevated pretreatment uPAR(I) was an independent predictor of overall survival (hazard ratio [HR] =1.39, 95 % confidence interval (CI) 1.17-1.66, p < 0.05, c-index= 0.70). Comparable results were observed for suPAR(I-III+II-III) (HR=1.48, 1.17-1.88, p < 0.0001, c-index 0.69). These findings were confirmed in the validation cohort, uPAR(I), p < 0.0001, c-index 0.65; suPAR(I-III+II-III), p < 0.0001, c-index 0.65. by using CA19-9 as an independent prognostic marker. CONCLUSIONS: Elevated plasma levels of uPAR(I) and suPAR(I-III+II-III) were associated with poor survival in patients with advanced PDAC independent of CA19-9 levels. These biomarkers have a potential prognostic value in this population.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Eefsen RL, Christensen IJ, Johansen AZ, et al. Elevated levels of cleaved soluble forms of urokinase-type plasminogen activator receptor are associated with poor survival in advanced pancreatic cancer. Eur J Cancer. 2025. PMID: 41205255. doi:10.1016/j.ejca.2025.116095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。